Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I/II Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia

NCT05345938 is registered in ClinicalTrials.gov with CSPC ZhongQi Pharmaceutical Technology Co., Ltd. as lead sponsor.

NCT NCT05345938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05345938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I/II Study to Evaluate the Safety, Tolerability, Efficacy, and Pharmacokinetics of Mitoxantrone Hydrochloride Liposome Injection in Subjects With Acute Myeloid Leukemia
Lead sponsor
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Phase
Phase 1/2
Overall status
Terminated
Start date
June 14, 2022
Completion date
November 19, 2022
Enrollment
1 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed or refractory acute myeloid leukemia (aml)